An open-label study of amisulpride in the treatment of mania

Journal of Clinical Psychiatry

Volumn 66, Issue 5, 2005, Pages 575-578

  Vieta, Eduard ^a   Ros, Salvador ^b   Goikolea, José Manuel ^a   Benabarre, Antonio ^a   Popova, Ekaterina ^a   Comes, Mercè ^a   Capapey, Jorge ^a   Sánchez Moreno, José ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; FLUNITRAZEPAM; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; LORAZEPAM; OLANZAPINE; OXCARBAZEPINE; PIMOZIDE; PROLACTIN; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BIPOLAR MANIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSIONS SCALE FOR BIPOLAR DISORDER MODIFIED; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; HUMAN; INSOMNIA; MALE; MANIA; MENTAL DISEASE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; XEROSTOMIA; YOUNG MANIA RATING SCALE;

EID: 19544381180     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0505     Document Type: Article

References (15)

1. Vieta E. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2003;16:23-27
2. Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001;61:2123-2150
3. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280: 83-97
4. Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002;12: 305-310
5. Lecrubier Y, Boyer P, Turjanski S, et al. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 1997;43:95-103
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
7. Peuskens J, Bech P, Möller HJ, et al. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res 1999;88:107-117
8. Colom F, Vieta E, Martinez-Aran A, et al. Versión española de una escala de evaluación de la manía: validez y fiabilidad de la Escala de Young. Med Clin (Barc) 2002;119:366-371
9. Bobes J, Bulbena A, Luque A, et al. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 items de la Escala de valoración de Hamilton para la evaluación de la depresión. Med Clin (Barc) 2003; 120:693-700
10. Vieta Pascual E, Torrent Font C, Martinez-Aran A, et al. Escala sencilla de evaluación del curso del trastorno bipolar: CGI-BP-M. Actas Esp Psiquiatr 2002;30:301-304
11. Chengappa KN, Baker RW, Saho L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003;5:1-5
12. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
13. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14:209-218
14. Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22
15. Vieta E, Herraiz M, Parramon G, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-19